Los Angeles Capital Management LLC Has $646,000 Stock Position in Replimune Group, Inc. (NASDAQ:REPL)

Los Angeles Capital Management LLC lifted its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 8.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 71,815 shares of the company’s stock after acquiring an additional 5,410 shares during the period. Los Angeles Capital Management LLC owned approximately 0.11% of Replimune Group worth $646,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Nisa Investment Advisors LLC grew its position in shares of Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Replimune Group in the fourth quarter valued at approximately $76,000. Diversified Trust Co acquired a new stake in Replimune Group during the first quarter worth approximately $94,000. China Universal Asset Management Co. Ltd. grew its position in Replimune Group by 72.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock worth $96,000 after buying an additional 4,975 shares in the last quarter. Finally, Arizona State Retirement System bought a new position in Replimune Group during the 2nd quarter worth $108,000. 92.53% of the stock is owned by institutional investors.

Insider Transactions at Replimune Group

In related news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 20.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on REPL shares. Barclays upped their target price on Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Wedbush reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Replimune Group in a research report on Thursday, June 6th. JPMorgan Chase & Co. decreased their target price on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research report on Tuesday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $16.20.

Replimune Group Stock Up 7.2 %

Shares of NASDAQ REPL opened at $11.13 on Friday. The company has a market cap of $683.55 million, a price-to-earnings ratio of -3.44 and a beta of 1.22. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $19.16. The stock has a 50-day moving average price of $10.05 and a two-hundred day moving average price of $8.34.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.10. As a group, analysts forecast that Replimune Group, Inc. will post -3.08 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.